Literature DB >> 20473914

Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors.

José Antonio López-Guerrero1, Isidro Machado, Katia Scotlandi, Rosa Noguera, Antonio Pellín, Samuel Navarro, Massimo Serra, Silvia Calabuig-Fariñas, Piero Picci, Antonio Llombart-Bosch.   

Abstract

More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, p21(Waf1/Cip1) , p27(Kip1) and Ki67 and the chromosomal alterations of the p53 and 9p21 locus by fluorescent in situ hybridization. We observed that expression of p53 (p = 0.025), p21(Waf1/Cip1) (p = 0.015) and p27(Kip1) (p = 0.013) was higher in disseminated than in localized disease. Furthermore, a cohort of 217 patients with localized disease was considered for studying the prognosis involvement of these factors on patient follow-up. The median follow-up was 39 months (range: 0.17-452) with an overall survival (OS) of 55%. Ki67 was expressed in 34% of cases and constituted an independent prognostic factor for progression free survival and OS independently of the type of treatment [hazard ratio of 2.0 (95% CI: 1.3-3.1; p = 0.003) and 1.9 (95% IC: 1.3-2.9; p = 0.007) for progression free survival and OS, respectively, being especially relevant in the group of patients which incorporated radiotherapy in their regimen schedules. In conclusion, this study demonstrates that Ki67 expression constitutes a valuable indicator of poor prognosis in localized ESFT.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20473914     DOI: 10.1002/ijc.25424

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?

Authors:  Isidro Machado; José A López-Guerrero; Samuel Navarro; Marco Alberghini; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2012-08-17       Impact factor: 4.064

2.  Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Daniel M Lerman; Michael J Monument; Elizabeth McIlvaine; Xiao-qiong Liu; Dali Huang; Laura Monovich; Natalie Beeler; Richard G Gorlick; Neyssa M Marina; Richard B Womer; Julia A Bridge; Mark D Krailo; R Lor Randall; Stephen L Lessnick
Journal:  Pediatr Blood Cancer       Date:  2014-12-02       Impact factor: 3.167

3.  Macrophage infiltration predicts a poor prognosis for human ewing sarcoma.

Authors:  Toshifumi Fujiwara; Jun-ichi Fukushi; Shunsaku Yamamoto; Yoshihiro Matsumoto; Nokitaka Setsu; Yoshinao Oda; Hisakata Yamada; Seiji Okada; Kosuke Watari; Mayumi Ono; Michihiko Kuwano; Satoshi Kamura; Keiichiro Iida; Yuko Okada; Mihoko Koga; Yukihide Iwamoto
Journal:  Am J Pathol       Date:  2011-07-21       Impact factor: 4.307

4.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

5.  A rare case of extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor developing in maxillary sinus of an old patient.

Authors:  Maithili Mandar Kulkarni; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Chitrangi Barpande
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

6.  Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis.

Authors:  Liangdong Jiang; Cheng Tao; Aiyong He
Journal:  Tumour Biol       Date:  2013-01-23

7.  Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

Authors:  Isidro Machado; José Antonio López Guerrero; Samuel Navarro; Empar Mayordomo; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

8.  Comparison of Latino and non-Latino patients with Ewing sarcoma.

Authors:  Jeremy Sharib; Andrew Horvai; Florette K Gray Hazard; Heike Daldrup-Link; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

9.  Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  BMC Clin Pathol       Date:  2012-05-03

10.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.